11 citations
,
May 2021 in “Asian Journal of Pharmaceutical and Clinical Research” Eclipta alba (Bhringraj) helps protect the liver and promotes hair growth.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
January 2023 in “Social Science Research Network” The document doesn't say if the treatment for hair loss worked.
83 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help children with alopecia areata regrow hair.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
October 2021 in “Journal of Investigative Dermatology” Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
December 2023 in “Panacea Journal of Medical Sciences” Alopecia areata is often linked to personal or family history of allergies and autoimmune diseases.
January 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Pediatric alopecia areata needs better treatments and psychological support.
July 2025 in “Journal of Research in Siddha Medicine” Eclipta alba extract is generally safe with mild liver and kidney changes at high doses.
3 citations
,
October 2020 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
1 citations
,
November 2016 in “Saengmyeong gwahag hoeji/Saengmyeong gwahak hoeji” New treatments for the autoimmune hair loss condition alopecia areata may include JAK inhibitors and other immunomodulators.
January 2025 in “SKIN The Journal of Cutaneous Medicine” January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
October 2014 in “Aktuelle Dermatologie” A 19-year-old with MRKHS developed complete hair loss, and treatment options were discussed.
42 citations
,
July 2013 in “Gene” IL-4 gene variation may increase the risk of alopecia areata in Turkish people.
14 citations
,
October 1974 in “Archives of Dermatology” Females with alopecia areata have more fingerprint arches.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
July 2024 in “International Journal of Medical Science and Clinical Research Studies” Alopecia Areata Incognita causes sudden hair loss in young females but usually has a better outcome than other types.
January 2025 in “Dermatologic Therapy” Alopecia areata may be linked to higher heart disease risk.
2 citations
,
February 2023 in “Journal of the American Academy of Dermatology” People with autism are more likely to develop alopecia areata than those without autism.
3 citations
,
August 2021 in “Clinical Case Reports” Genetic testing is crucial before giving azathioprine to avoid severe side effects.
The herbal shampoo with Harsinghar works better against dandruff than a commercial product.
1 citations
,
October 2014 in “Annals of oncology” Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.
June 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” A mutation in the KRT82 gene is significantly associated with Alopecia Areata.
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.